Y-mAbs Therapeutics, Inc.
YMAB
$8.53
$0.010.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.53M | 20.90M | 26.50M | 18.46M | 22.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.53M | 20.90M | 26.50M | 18.46M | 22.80M |
| Cost of Revenue | 2.71M | 3.00M | 7.84M | 2.25M | 3.01M |
| Gross Profit | 16.81M | 17.90M | 18.65M | 16.21M | 19.78M |
| SG&A Expenses | 11.46M | 12.73M | 11.87M | 13.06M | 17.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.13M | 26.52M | 30.86M | 26.31M | 32.59M |
| Operating Income | -5.60M | -5.62M | -4.36M | -7.85M | -9.79M |
| Income Before Tax | -3.23M | -5.19M | -7.54M | -6.65M | -9.15M |
| Income Tax Expenses | 7.00K | 5.00K | -752.00K | 346.00K | 100.00K |
| Earnings from Continuing Operations | -3.24M | -5.20M | -6.79M | -7.00M | -9.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.24M | -5.20M | -6.79M | -7.00M | -9.25M |
| EBIT | -5.60M | -5.62M | -4.36M | -7.85M | -9.79M |
| EBITDA | -5.55M | -5.55M | -4.26M | -7.73M | -9.64M |
| EPS Basic | -0.07 | -0.12 | -0.15 | -0.16 | -0.21 |
| Normalized Basic EPS | -0.04 | -0.06 | -0.08 | -0.08 | -0.13 |
| EPS Diluted | -0.07 | -0.12 | -0.15 | -0.16 | -0.21 |
| Normalized Diluted EPS | -0.04 | -0.06 | -0.08 | -0.08 | -0.13 |
| Average Basic Shares Outstanding | 45.32M | 45.10M | 44.88M | 44.63M | 44.02M |
| Average Diluted Shares Outstanding | 45.32M | 45.10M | 44.88M | 44.63M | 44.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |